San Sebastián, Spain–headquartered Viralgen, has opened a new factory in Basque Country in northern Spain.
The company focuses on manufacturing adeno-associated virus (AAV) vectors, which are used in gene therapy and some vaccines.
Since 2018, Viralgen has offered AAV manufacturing for customers working in preclinical through Phase 2 development programs. The company has licensed its Pro10 AAV platform from AskBio.
The first phase of investment in the facility represents a €70 million investment (approximately $83 million). The company plans on spending a total of €120 million (roughly $142 million) after the construction of two additional buildings is completed.
A total of 250 people will work in the facility in 2022. Of that total, some 130 will be new hires.
Formed in 2017, Viralgen was a joint venture…